Auransa

Auransa is pioneering a biology-first AI platform that processes heterogeneous human disease data—including over 500,000 gene expression profiles across 70+ diseases—to rapidly identify novel drug candidates with high predictivity. The company has advanced its lead asset, AU-409, into Phase 1 clinical trials for liver cancer in the US and Asia, and is developing AU-018 to improve the safety of anthracycline chemotherapy. Led by a team with deep experience in genomics, data science, and drug discovery from major pharmaceutical companies, Auransa collaborates with leading pharma and academic institutions to translate its discoveries into meaningful patient benefits.

A proprietary AI platform that processes massive, heterogeneous human disease data (e.g., 525K+ gene expression profiles across 70+ diseases) to rapidly identify and validate novel drug candidates with high predictivity, focusing exclusively on human biology to bridge the translational gap.

Total raised: $25.5M

Faces competition from other AI-driven biotechs (e.g., Recursion, Exscientia) and from established/pharma players in liver cancer (e.g., Roche, Bayer) and cardioprotection. Auransa differentiates by its exclusive use of human disease data, biology-first approach, and claimed high predictivity that has already generated a clinical-stage asset.